Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

STOCKHOLM, SWEDEN ( - Dr. J. J. Aning presented an abstract on a cohort of 853 men (mean age of 65 years) with low- and intermediate-risk prostate cancer from Vancouver, Canada who were managed by active surveillance (AS). The primary aim of their study was to identify risk factors which lead to progression of prostate cancer while under AS. All men were 75-years-old or younger and had undergone restaging prostate biopsy, with at least 6 months of follow up. Their AS protocol involved 6 monthly PSA and DRE reviews in addition to rebiopsy of the prostate, with planned repeat biopsies every 2 years. Prostate cancer risk status was defined by National Comprehensive Cancer Network guideline criteria.

eauMean PSA at diagnosis was 6.5ng/ml, with mean follow up of 5 years. Of the cohort, 50%, 27% and 23% were classified as very low-, low-, or intermediate-risk prostate cancer, respectively. Three hundred-nine men progressed to active treatment, most commonly due to grade progression at re-biopsy (62%), followed by patient choice (10%), and PSA progression (8%). Dr. Aning and colleagues reported actuarial probability of remaining on AS at 1, 2, 5, 8 years: 95%, 81%, 60%, and 47%, respectively. They reported a significant difference in the risk of progression to treatment between very low risk and other groups (p = 0.002), but not between low and intermediate risk groups (p= 0.481). On multivariate analysis, they determined that increasing number of positive biopsy cores at diagnosis and PSA density were significant predictors of progression to treatment (p= < 0.001). Negative prostate biopsy prior to diagnosis was found to be a significant negative predictor of progression to treatment (p=0.01). Of those treated, 4% (n=15) had biochemical recurrence. Overall survival of their AS cohort was 97%, with 1 death due to prostate cancer. Institutions continue to show evidence that AS is certainly a safe and viable option in select cohorts of men with diagnosis of prostate cancer.

Presented by J. J. Aning at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden

Vancouver Prostate Centre, Vancouver, Canada

Written by Reza Mehrazin, MD, medical writer for


Editor selected abstracts and commentaries
Clinical Trials
Searchable data base of currently enrolling clinical trials
Upcoming urology industry events
February 24, 2018 / Charleston Marriott
Advances in Cancer Immunotherapy™ - Charleston, SC
February 24, 2018 /
2018 IUA Annual Meeting
February 26-27, 2018 / The Royal Marsden Hospital
MediSens – The European Medical Imaging Conference
February 27-March 3, 2018 /
SUFU 2018 Winter Meeting
March 1-3, 2018 / Omni Amelia Island Plantation Resort, Fernandina Beach, FL
75th Annual Meeting Mid-Atlantic Section of the American Urological Association
Print publications focusing on urological cancer treatments through original commentary & articles

Everyday Urology™ - Oncology Insights

From the Editor

Prostate Cancer and Prostatic Diseases

From the Editor